1/2
Export Ready

BORTLIEVA (BORTEZOMIB INJECTION IP 3.5MG /VIAL

Sold by RADHAKRUSHNA MEDICALS · Distributor, Exporter, Wholesaler · Yavatmal, Maharashtra, India

Price
Price on request
In stock
Minimum order: 1 Piece

Export Snapshot

MOQ
1 Piece
Lead time
On request
Packaging
Standard export packaging
Shelf life / longevity
As per product specification
HSN Code
30049095
Origin
India
Port of dispatch
On request
Export markets served
United States flag US Philippines flag PH Smaller Territories of the UK flag XG United Kingdom flag GB Bangladesh flag BD +46 others
Values shown are for RADHAKRUSHNA MEDICALS.
Suitable for

Importers · Distributors · Wholesalers

Know your supplier

RADHAKRUSHNA MEDICALS is a Distributor, Exporter, Wholesaler based in Yavatmal Maharashtra India.

Yavatmal Dispatch on request Verified seller
RADHAKRUSHNA MEDICALS logo

Distributor, Exporter, Wholesaler · Yavatmal, Maharashtra, India

"Radhakrushna Medicals: Your Destination for Critical Care & Speciality Medicines. Surgical Suture Vaccines  "

Registered address: Yavatmal, India. Industry: Healthcare, Medical Supplies & Pharmaceuticals > Drugs & Pharmaceuticals.

Established
2022
Employees
1–10
GST
27AEMPT2491Q2ZF
IEC code
AEMPT2491Q
Export markets
United States flag US Philippines flag PH Smaller Territories of the UK flag XG United Kingdom flag GB Bangladesh flag BD +46 others
GlobalLinker Member Since
Feb 2026
Turnover
$50,000 - $250,000
Incorporation Type
On request
Product details

What are the specifications of this product?

Overview

Bortezomib Injection IP 3.5mgBrand Name BORTELIEVA 3.5MGComposition Bortezomib Injection IP 3.5mgManufacture By Allieva Pharma Private LimitedForm InjectionPacking VialCountry Of Origin India ANTI CANCER MEDICINE USE IN ONCOLOGY PRESCRIPTION DRUGS SCHEDUED DRUGSPrescription Required

Product Description

Description
BORTLIEVA contains Bortezomib, a proteasome inhibitor used in cancer treatment. It works by blocking proteasomes in cells, leading to accumulation of proteins and apoptosis (cell death) of cancer cells.

Uses
Bortezomib is used in adults for:

1. Multiple myeloma
     – Newly diagnosed or relapsed/refractory

2. Mantle cell lymphoma
     – Previously treated patients

3. Sometimes in combination with other chemotherapies for certain hematologic cancers.

Side Effects
Common side effects:

•  Fatigue, weakness

•  Peripheral neuropathy (tingling/numbness)

•  Nausea, vomiting

•  Diarrhea or constipation

•  Low blood counts (thrombocytopenia, neutropenia)

Serious side effects:

•  Severe infections

•  Severe neuropathy

•  Heart problems (rare)

•  Liver function abnormalities

Monitor blood counts and liver function regularly.

Dosage
•  1.3 mg/m² IV or SC on Days 1, 4, 8, 11 of a 21-day cycle (common regimen)

•  Dose may be adjusted based on side effects or prior therapies

•  Can be given intravenously (IV) or subcutaneously (SC)

NOTE: This medicine should be taken only under a doctor’s supervision.

Description provided by RADHAKRUSHNA MEDICALS.

Specifications

Product Name BORTLIEVA (Bortezomib Injection IP 3.5mg)
Dosage Strength 3.5 mg per vial
Active Pharmaceutical Ingredient (API) Bortezomib
Formulation Injection
Route of Administration IV / SC
Therapeutic Category Anti-Cancer, Oncology
Indications Multiple Myeloma, Mantle Cell Lymphoma
Manufacturer Allieva Pharma Private Limited
Country of Origin India
Prescription Requirement Yes
Packaging Type Vial
MOQ 1 Piece
Storage Conditions Store as per physician's instructions

Use cases

Category Pharmaceuticals > Oncology Medicines > Anti-Cancer Injections
Primary application Wholesale, distribution, and international sourcing
Brand Not specified
Product type Product

Logistics & handling

Lead time On request
Packaging As per buyer requirement
Storage condition As recommended by supplier
Origin India
Form As listed by supplier

Commercials (this seller)

Minimum order 1 Piece
Lead time On request
Payment terms As per negotiated commercial agreement.
Buyer questions

Frequently asked by buyers

Common questions B2B buyers ask before sourcing BORTLIEVA (BORTEZOMIB INJECTION IP 3.5MG /VIAL. Answers compiled from verified sellers' commercial terms and platform data.

Q: What cancers is BORTLIEVA Injection indicated for?
A: BORTLIEVA is indicated for treating multiple myeloma—both newly diagnosed and relapsed/refractory—and mantle cell lymphoma in previously treated patients.
Q: How is BORTLIEVA administered?
A: It can be administered either intravenously (IV) or subcutaneously (SC) in cycles, typically 1.3 mg/m² on Days 1, 4, 8, and 11 of a 21-day treatment cycle.
Q: Are there any special storage instructions for BORTLIEVA Injection?
A: BORTLIEVA must be stored as per the manufacturer’s and physician’s recommendations to maintain stability, typically in a controlled temperature environment.
Q: What are the common side effects of BORTLIEVA Injection?
A: Common side effects include fatigue, peripheral neuropathy, nausea, vomiting, diarrhea or constipation, and blood count abnormalities such as thrombocytopenia and neutropenia.
Q: Is a prescription required to purchase BORTLIEVA?
A: Yes, BORTLIEVA is a prescription-only and scheduled anti-cancer drug, requiring authorization from a licensed healthcare professional.
Question not answered? Ask sellers directly — typical response within 4 hours.
BORTLIEVA (BORTEZOMIB INJECTION IP 3.5MG /VIAL
BORTLIEVA (BORTEZOMIB INJECTION IP 3.5MG /VIAL
Price on request · MOQ 1Piece